Could poop transplants treat diabetes and heart disease?

NCT ID NCT07421947

Not yet recruiting Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether fecal microbiota transplantation (FMT) can change the gut microbiome in 30 people with type 2 diabetes and stable coronary artery disease. Participants receive processed stool from healthy donors via colonoscopy. The goal is to see if this alters gut bacteria and possibly improves metabolic and heart health markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplantation (processed stool from healthy donors given via colonoscopy)
What this could lead to: If successful, this could point toward a new way to treat type 2 diabetes and heart disease by adjusting gut bacteria.
What could go wrong: This is a very small pilot study (30 people) with no control group, so results may not be reliable or generalizable. The procedure carries risks like infection or bowel perforation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Inflammation type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.